Beneficial gut bacteria can reduce the risk of cardiovascular disease

Recently, patrice Carney's team at the Leuven Institute for Drug Research at the University of Leuven in Belgium, in collaboration with Professor William de Foss of the University of Wagningen in the Netherlands, discovered a beneficial gut bacteria (Akkermansia muciniphila) that reduces the incidence of obesity and type 2 diabetes in mice, and that Akkermansia, treated with pasteurization, can provide mice with more effective protection against cardiovascular disease.
these findings, a team at the University of Leuven conducted a clinical study with the hope of applying the bacteria to humans. The researchers recruited obese volunteers to take Akkermansia. All of the volunteers showed insulin tolerance and metabolic syndrome. The volunteers were randomly divided into three groups (placebo, live and pasteurized) and asked not to change their eating habits or daily activities. Akkermansia is only available to these volunteers in the form of nutritional supplements.
In the end, the study observed that in volunteers in the live and pasteurized groups, the nutritional supplement was highly dependent and had no side effects, along with signs of reduced liver inflammation, a slight drop in weight, and lower cholesterol levels. Instead, the placebo group's metabolic parameters continued to deteriorate over time.
researchers say the study has tentatively demonstrated the feasibility of giving people pasteurized Akkermansia in the form of food supplements, as well as the effectiveness of Akkermansia-based dietary supplements in reducing the risk of cardiovascular disease. In the future, researchers will further validate and refine the original findings, and plan to commercialize the bacterial food supplement by 2021. (Source: Qiu Chenggang, China Science Journal)
related paper information: